Drugs / NBI-1065890
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07365462 | Feb 2026 → Feb 2027 expected | tardive dyskinesia | Neurocrine Biosciences | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-03-28 | Neurocrine Biosciences | Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults gcs-web.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NBI-1065890 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07365462 ↗ |
| Route | Oral | “Oral administration” NCT07365462 ↗ |